l-carnitine in management of valproic acid induced hyperammonemia Mechanism (VPA)-induced hyperammonemia. (1) VPA is A Case of Valproate-Induced Hyperammonemic
Description
Patients with NT2 do not present with cataplexy, although they present most of the symptoms that characterize NT1 4
This helps maintain a steady level in the body for consistent energy and metabolism
In total, 17 randomized controlled trials consisting of 1625 heart failure patients receiving L-C were included in this meta-analysis
10.1128/JB.184.14.4044-4047.2002
Schulman, S
Moreover, the intestinal microbiota contributes to the progression of host diseases through its metabolites, including short chain fatty acids (SCFAs), bile acids, tryptophan, branched-chain amino acids, and uremic toxins [5]
